BATRA vs MSGS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BATRA and MSGS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BATRA and MSGS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Atlanta Braves Holdings, Inc. was spun off from Liberty Media in 2023 and, through its Braves Holdings subsidiary, owns the Atlanta Braves baseball club, their home at Truist Park, and The Battery Atlanta, a retail, office, hotel, and entertainment district built around the stadium. The company reports in two segments: Baseball (ticket sales, concessions, local and national broadcasting rights, sponsorships, premium seating, retail, and shared MLB revenue) and Mixed-Use Development (rental income and reimbursements from Battery Atlanta tenants). It is one of the only ways public investors can own a single major North American sports team directly.

Full BATRA guide

Madison Square Garden Sports Corp. owns and operates the New York Knickerbockers of the NBA and the New York Rangers of the NHL, along with two development-league affiliates and a professional sports team performance business. Its revenue comes from ticket sales and premium seating, local media rights fees, sponsorship and signage, food and merchandise at games, and its share of leaguewide national media and licensing money. The company does not own Madison Square Garden itself: the arena sits inside MSG Entertainment, and the Knicks and Rangers pay to play there under long-term arrangements, which is why the reported financials look thinner than the size of the underlying assets suggests. Revenue for the trailing twelve months through June 2026 is roughly ~$1.15 billion against a market capitalization of about ~$9.6 billion, a ratio that only makes sense once you treat the company as an asset holder rather than an operating business.

Full MSGS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BATRA drivers: Scarcity value of an MLB franchise; Battery Atlanta mixed-use development.
• MSGS drivers: Franchise scarcity; The Knicks and Rangers separation, now scheduled.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Reported earnings are thin and seasonal: the company lost roughly $64 million on a GAAP basis over the twelve months to June 2026, and operating profit can be small or negative in off-season quarters, so the stock can trade well above what current cash flow alone would justify. For MSGS, the Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BATRA if you believe its drivers more; MSGS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BATRA and MSGS guides.

BATRA. As of October 2026, Atlanta Braves Holdings carries a market capitalization of roughly $3.5 billion on about $750 million of trailing revenue, a price-to-sales ratio near 4.7 times. Trailing and forward earnings multiples are not meaningful because the company reports GAAP losses, so the stock is usually valued against estimated franchise worth plus the Battery Atlanta real estate, less debt. Recent private team sales and an activist call for a sale have pushed that framing to the front.

MSGS. Conventional earnings multiples do not describe this stock: on ~$8 million of trailing net income the trailing P/E is above 1,000x, and forward EPS is negative because the September quarter is the off-season. The more common framework is a sum-of-the-parts, comparing the market capitalization of about ~$9.6 billion against combined franchise appraisals near ~$13.5 billion and then adjusting for ~$1.16 billion of debt and for the discount attached to a controlled structure. That gap narrowed as the shares rose ~82% over the past year off a 52-week low near ~$208, and from October 27, 2026 the market will price the Knicks (MSGK) and Rangers (MSGR) separately.

Headline figures (approximate, October 2026): BATRA shows revenue (ttm through q2 2026) ~$750M, revenue (q2 2026) ~$305M, down ~2% year over year, net income (ttm) ~-$64M (loss), P/E not meaningful, operating margin (ttm) ~-6%; MSGS shows share price ~$397 (October 16, 2026), market capitalization ~$9.6 billion, revenue (ttm, through june 2026) ~$1.15 billion, net income (ttm) ~$8 million (EPS ~$0.32).

BATRA and MSGS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BATRA and MSGS exposure against your real portfolio. It is not an investment adviser.